An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Latest Information Update: 10 Apr 2025
At a glance
- Drugs Mavorixafor (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors X4 Pharmaceuticals
Most Recent Events
- 03 Apr 2025 Status changed from not yet recruiting to recruiting.
- 11 Mar 2025 New trial record